Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways

The European biotech sector is evolving as it seeks to bridge the gap between academic research and commercial drug development. While Europe possesses world-class science, researchers often lack the entrepreneurial training necessary to navigate funding and business strategy compared to their US counterparts. Industry leaders emphasize shifting focus toward fundamental biological mechanisms—such as mitochondrial health and women’s health—rather than relying on hyper-complex, multi-paratopic molecular constructs. Recent clinical setbacks, specifically regarding Lp(a) targets, highlight the critical need for rigorous patient selection and deeper target validation beyond simple genetic associations. As the ecosystem matures, there is a growing push to build local infrastructure that supports company growth, moving away from the necessity of relocating to hubs like Boston to achieve long-term success.